Provexis PLC Delay in Accounts and AIM Suspension Latest FTSE Price

Highlights

• Provexis PLC announces a delay in publishing annual accounts, leading to a temporary suspension of its shares from AIM.

• The company continues its focus on Fruitflow®, its scientifically developed functional ingredient with multiple health benefits.

• Broader market performance can be contextualised by indices such as the FTSE AIM UK 50 INDEX and the latest ftse price.

Provexis PLC delays annual accounts, triggering AIM suspension, while Fruitflow® remains central to its commercial focus and global partnerships.

Provexis PLC, listed under the ticker (LSE:PXS), is a business that operates in the healthcare and biotechnology space with a focus on functional food innovation. It is traded on AIM, which forms part of the broader ecosystem of indices including the FTSE AIM UK 50 INDEX. The company’s primary asset is Fruitflow®, a proprietary heart-health functional ingredient that has achieved recognition for its scientifically validated impact on platelet activity and circulation. The wider framework of indices such as the FTSE 100, FTSE 250, and FTSE 350 are often used as benchmarks for assessing the positioning of smaller listed companies, while the latest ftse price reflects daily market conditions and overall trends.

Delay in Annual Accounts

Provexis announced that the audit of its annual accounts for the period ending March has not been finalised within the required timeframe set under AIM regulations. This delay is linked to the company’s transition to a new auditing partner, RPG Crouch Chapman LLP, which is undertaking its first year in this role. The company has indicated that it continues to work with its auditors to complete the process promptly, with publication of results anticipated soon.

Temporary Suspension on AIM

The company confirmed that, due to the delay in the completion of accounts, its shares would face temporary suspension from trading on AIM. Suspension in such cases is standard under the rules of the exchange and is expected to be lifted upon the release of the outstanding financial statements. AIM, as part of the London Stock Exchange’s broader structure, provides a platform for growth businesses, and its regulatory framework ensures transparency and accountability from listed entities.

The Central Role of Fruitflow®

At the core of Provexis’ operations lies Fruitflow®, a natural ingredient designed to promote healthy blood flow. Fruitflow® supports normal platelet function, helping circulation remain smooth and efficient. It is free of lycopene and contains a combination of bioactive compounds that contribute to its effectiveness. Fruitflow® has been validated in peer-reviewed publications and holds a European Food Safety Authority health claim stating that consumption contributes to healthy blood flow by maintaining normal platelet aggregation.

Applications of Fruitflow®

The functional properties of Fruitflow® extend beyond cardiovascular health. Provexis has highlighted research demonstrating that Fruitflow® can help mitigate exercise-induced inflammation, support healthy blood pressure, and counter the negative effects of air pollution on cardiovascular function. Studies have also suggested a role in modulating the gut microbiome, with measurable impacts on markers such as TMAO, linked to heart health. This breadth of application enhances its importance within the nutritional sciences sector.

Commercial Expansion of Fruitflow®

Provexis has maintained a long-term collaboration with BYHEALTH, a major dietary supplement company in China. The partnership is aimed at supporting the development and introduction of Fruitflow®-based products to the Chinese market. To meet regulatory requirements in China, clinical studies have been undertaken to demonstrate the efficacy and safety of the ingredient. Several studies have already been completed with positive outcomes, and BYHEALTH has submitted applications for regulatory clearance linked to new permitted health function claims. This represents an important step towards broader product access in one of the world’s largest supplement markets.

Production and Supply Chain Updates

Provexis has confirmed that it has sold through its remaining inventory of Fruitflow II SD, a specific format of the ingredient. A new production run has been completed with outsourced supply chain partners, ensuring continuity of supply. Delivery of the new batch has been slightly delayed but is scheduled within the current quarter. This continuity is important to meet ongoing demand from customers and to support future planned growth.

Direct-to-Consumer Products

Alongside its partnerships, Provexis also markets a dietary supplement that combines Fruitflow® with Omega-3. This product is available through the company’s official website and leading e-commerce platforms, providing consumers with direct access to the functional benefits of Fruitflow®. The dual approach of business-to-business partnerships and direct enhances the reach and visibility of the ingredient.

How the Suspension Impacts Provexis

While the suspension affects the trading of shares, it does not impede the company’s ongoing commercial activities. Provexis continues to manufacture and distribute its products, manage customer relationships, and develop international partnerships. The temporary nature of the suspension means that once accounts are published, trading in shares is expected to resume under standard conditions.

Scientific Recognition of Fruitflow®

Fruitflow® is notable for being the only natural antiplatelet with an approved health claim from the European Food Safety Authority. Its effectiveness has been compared to traditional compounds used for platelet management but with a gentler and reversible action. Unlike pharmaceuticals, Fruitflow® does not cause associated side effects, making it an appealing option within functional foods. The ingredient’s validation through clinical research strengthens its credibility within both scientific and commercial contexts.

Provexis and the Broader Market Indices

Provexis’ listing on AIM situates it within a specialised segment of the London Stock Exchange. The FTSE AIM 100 Index tracks the largest AIM companies by market capitalisation and provides a measure of performance across this segment. Broader benchmarks such as the FTSE 100 and FTSE 350 reflect trends in larger, more established companies, offering useful context for comparing market behaviour. Monitoring the latest ftse price provides insight into how wider economic and sector conditions align with company-specific developments.

Upcoming Annual General Meeting

Provexis has confirmed that its Annual General Meeting is scheduled for November. The AGM will allow the company to provide updates to shareholders on operational matters, including the progress of the Fruitflow® product line, international collaborations, and future priorities. AGMs also provide a platform for formal decisions to be made regarding corporate governance and compliance.

RNS and Transparency in Communication

The announcement regarding the delay in accounts was made through the London Stock Exchange’s Regulatory News Service (RNS). This service ensures that official company updates are communicated transparently to the market. By disclosing information through RNS, companies maintain compliance with regulatory obligations and provide stakeholders with accurate, timely updates.

Healthcare and Functional Nutrition Context

Provexis operates within the growing field of functional nutrition, which integrates food-based solutions to support health beyond basic nutrition. Ingredients like Fruitflow® are part of this movement, offering measurable contributions to specific health outcomes. Within the UK and globally, demand for functional foods and supplements continues to rise, placing Provexis in a sector of growing relevance.